What Researchers Did
Researchers conducted a review of preclinical and clinical studies investigating the use of normobaric and hyperbaric oxygen therapies for acute focal cerebral ischemia.
What They Found
Preclinical studies largely showed beneficial effects of normobaric (NBO) and hyperbaric oxygen (HBO) therapies, particularly with early HBO application and high pressures, by stabilizing the blood-brain barrier and reducing inflammation. However, clinical trials yielded mixed results, with NBO showing positive outcomes in one trial, while HBO failed to demonstrate efficacy in three randomized trials.
What This Means for Canadian Patients
Currently, normobaric and hyperbaric oxygen therapies are not standard treatments for acute ischemic stroke, as their clinical efficacy remains largely unproven despite promising preclinical data. Canadian patients should rely on established stroke treatments and consult their healthcare providers for current best practices.
Canadian Relevance
This review does not have a direct Canadian connection.
Study Limitations
The review highlights the ongoing challenge of translating promising preclinical findings into effective clinical treatments for acute ischemic stroke.